All News
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.
Read Article
Remicade Patent Infringements Denied: Opens Door for New Biosimilars
A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.
Read Article
Fewer Psoriasis Patients Satisfied with Current Treatments
A new national survey in the United States of nearly 600 individuals with psoriasis, reveals that although patients have numerous treatment options, they have difficulty finding treatment plans that work. In addition, respondents reported a heavy emotional toll, with many feeling isolated and stigmatized due to the condition.
Read Article
Serious Infections are Not Increased in HIV Patients Treated with TNF Inhibitors
Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.
Read Article
Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai
Read Article
RAPID3: An Effective Assessment Tool in Spondyloarthritis
Serial biomarker or clinical metric assessments are ubiquitous and commonly used to assess patients with rheumatoid arthritis (HAQ, CDAI, RAPID3), lupus (C3, C4, dsDNA) and gout (uric acid). But numerous disorders are either harder to assess or have tools or metrics that that are not commonly used.
Read Article
Long-Term Safety of Adalimumab Reviewed
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
Read Article
Novel Rise of Combined Dermatology-Rheumatology Clinics
Rheumatology News has a novel online report about combined rheumatology-dermatology clinics. In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).
Read Article
RheumNow Week in Review – 22 July 2016
From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.
Read Article
FDA Panel Recommends Brodalumab Approval in Psoriasis
Valeant Pharmaceuticals International's experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.
Read Article
DEXA Still Needed While on Bisphosphonates
Reuters reports that a study of 6629 Canadian women with osteoporosis taking bisphosphonates found that nearly one in five had a decrease in bone density while on medication. (Citation source: http://buff.ly/2afb7nj)
Read Article
Prevalence of Spondyloarthropathy in Fibromyalgia
With the introduction of ASAS criteria for the diagnosis of axial and peripheral spondyloarthropathy, there has been a debate about whether patients with fibromyalgia (FM) could be mistaken for a spondyloarthropathy, or vice versa.
Read Article
SAPHO Syndrome Revisted
SAPHO is an acronym that describes a constellation of findings (synovitis, acne, pustulosis, hyperostosis, and osteitis) that defines this rare syndrome.
Read Article
RheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee
The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.
Read Article
FDA Says Cryotherapy Lacks Evidence, Poses Risks
Cryotherapy is a non-FDA approved treatment that has been promoted to treat post-athletic injury, osteoarthritis,rheumatoid arthritis, fibromyalgia, alzheimers, migraines, asthma, multiple sclerosis, etc. Cryotherapy may be as simple as ice packs on a localized portion of the body, such as the lower back, or may involve whole body cryotherapy.
Read Article
Cancer Risk Lower with TNF inhibitors in Rheumatoid Arthritis
Since the introduction of TNF inhibitors nearly 20 years ago, concerns over a potential associated cancer risk have abounded. The recent ACR RA treatment guidelines have addressed this recently, stating that patients with any solid tumor cancer or risk thereof should be treated as if they ha
Read Article
AS Diagnosis Linked to CVD Risk
Prevalent patients with ankylosing spondylitis (AS) face a 30–50% increased risk of acute coronary, cerebrovascular, and thromboembolic events compared with the general population.
Read Article
RheumNow Week in Review – 24 June 2016
Dr. Cush reviews highlights published this week at RheumNow.com.
Read Article
Predictors of Progression in Early Inflammatory Polyarthritis
A substantial, but unclear, percentage of patients presenting with new onset inflammatory polyarthritis (IP) will spontaneously remit, while others may persist and develop rheumatoid arthritis (RA).
Read Article
